Home
- Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P.
- Natrol Appoints Vincent Andrich VP Sales for Prolab Division
- Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results
- Body Shop Reports 24.8 Mil Euro Sales Revenues
- Supplement Group Targets Consumer Education
- Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing
- ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market
- Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products
- Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth
- Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities
- ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products
- Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace
- Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO
- drugstore.com Expects to Reach Profitability Target in 2003
- Human Genome Project Leads to Innovative Healthcare
- NPIcenter’s Career Center targets nutraceutical Industry
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders
- Editorial: An Exercise in Synergy
- NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids
- LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway
- Natural Health Trends Corp. Launches Lexxus Taiwan
- New TrimFit® Bars Redefine Energy Bar Category
- New TrimFit® Bars Redefine Energy Bar Category
- Probiata® Offers Safe, Natural and Effective Alternative
- Alive & Well with Michelle Harris
- Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com
- Consumers Search for Healthy Cleaning Products That Work
- Nordic Naturals: Omega 3 Fatty Acids
- Cyanotech Names Bob Capelli as Director of Sales
- Nutraceutical Clinical Laboratories International, Inc., Secures $2 Million in Funding
- KAVA ADVISORY: Health Canada is advising consumers not to use any products containing kava
- IADSA workshop keeps the focus on Latin America
Regulators from Argentina, Chile and Brazil have taken part in workshop in Argentina organised by the International Alliance of Dietary/Food Supplement Associations (IADSA) to address global, regional and national regulatory trends. Held last month in Buenos Aires, the workshop gave the representatives the opportunity to learn about other regulatory systems in the area of dietary supplements.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Mineral Resources International, Inc. Issues Cease and Desist to Desquera Worldwide Regarding Unlawful Use of Trademarks in Malaysia
Mineral Resources International, Inc. (MRI) announced it has directed the issuance of a cease and desist letter to Desquera Worldwide Sdn Bhd regarding the sale of products labeled with the Trace Minerals Research® and ConcenTrace® brand names.
- Defendants in International Spam Operation Settle FTC Charges; New Canadian Defendants Identified
Defendants in an operation that sold bogus weight loss supplements through illegal spam e-mail have settled Federal Trade Commission charges that their operation violated federal laws. The settlement bars them from making false or unsubstantiated claims about health benefits of any food, drug, or dietary supplements; bars violations of the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, known as the CAN-SPAM Act; and requires them to give up $29,000 in ill-gotten gains.
- Defendants in International Spam Operation Settle FTC Charges; New Canadian Defendants Identified
Defendants in an operation that sold bogus weight loss supplements through illegal spam e-mail have settled Federal Trade Commission charges that their operation violated federal laws. The settlement bars them from making false or unsubstantiated claims about health benefits of any food, drug, or dietary supplements; bars violations of the Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003, known as the CAN-SPAM Act; and requires them to give up $29,000 in ill-gotten gains.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Clarinol(TM) CLA: Now GRAS-Approved
Lipid Nutrition has announced that FDA has issued a ‘no objection letter’ to the GRAS petition for Clarinol(TM) CLA, confirming its 'GRAS' status.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Federal Authorities Seize Xiadafil VIP Tablets After Company Refuses to Recall Product
At the request of the U.S. Food and Drug Administration, U.S. Marshals seized nearly $74,000 worth of Xiadafil VIP tablets, Lots 6K029 and 6K209-SEI, distributed by SEI Pharmaceuticals, Inc. of Miami, Fla. Although marketed as a dietary supplement to treat erectile dysfunction (ED) and for sexual enhancement, these lots represent an illegally marketed drug containing an undeclared ingredient.
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Cognis’ Tonalin® CLA Achieves FDA GRAS Status
Cognis Nutrition and Health has announced that the U.S. Food and Drug Administration (FDA) issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232).
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Novel food catalogue clarity reassuring but concerns remain says EHPM
European trade organisation EHPM has said it is ‘reassured’ by a statement from the European Commission that its recently published novel food catalogue is not legally binding for EU Member States, but has held concerns that listing an ingredient in the catalogue could prejudice its members’ products commercial viability because it may in practice be considered by some national authorities as a novel food ingredient.
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Capsugel Obtains Australia’s TGA Certification For Its Licaps® Liquid-Fill Capsule Manufacturing Facility
Capsugel has announced that it has received certification from the Therapeutic Goods Administration (TGA) for its Licaps® liquid-fill capsule production facility in Greenwood, S.C. (USA).
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Health claims based only on human intervention studies not practical says IADSA
Commenting on the latest draft Codex Alimentarius recommendations for the scientific basis of health claims, IADSA said that while the clinical trial model is one source of scientific data, it is not practical when applied to the reduction of risk of disease in persons generally regarded as ‘healthy’.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- Makers of Airborne Settle FTC Charges of Deceptive Advertising Agreement Brings Total Settlement Funds to $30 Million
Airborne Health, Inc., the Bonita Springs, Florida maker of the popular Airborne Effervescent Health Formula, an effervescent tablet marketed as a cold prevention and treatment remedy, has agreed to pay up to $30 million to settle Federal Trade Commission charges that it did not have adequate evidence to support its advertising claims. If the settlement is approved by the court, it will prohibit the defendants from making false and unsubstantiated cold prevention, germ-fighting, and efficacy claims. The monetary judgment will be satisfied by the defendants’ adding $6.5 million to the funds they have already agreed to pay to settle a related private class-action lawsuit, bringing the total settlement fund to $30 million.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- FDA Announces a Final Rule in Regards to Soluble Fiber Sources
The Food and Drug Administration (FDA) is adopting as a final rule, without
change, the provisions of the interim final rule (IFR) that amended the
regulation authorizing a health claim on soluble fiber from certain foods and
risk of coronary heart disease (CHD), to add barley betafiber as an additional
eligible source of beta-glucan soluble fiber. FDA is taking this action to
complete the rulemaking initiated with the IFR.
- Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs
Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud.
- Four "Hi-Tech Pharmaceuticals" Case Defendants Plead Guilty to Importing and Distributing "Knock-Off" Prescription Drugs
Four men based in Georgia, USA, have plead guilty to conspiring to import and distribute adulterated, mislabeled and unapproved new drugs, and to commit mail and wire fraud.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EFSA Adopts First Opinions on Health Claims Made on Foods Relating to Disease Risk Reduction and Children's Health
EFSA’s Panel on dietetic products, nutrition and allergies (NDA) has adopted its first series of opinions on claims referring to the reduction of disease risk, and children's development and health. Scientists of the NDA Panel examined the scientific evidence for 8 claims, 5 of which related to children’s health and 3 to disease risk reduction.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- EU as a global exporter of regulation
Simon Pettman, Director of international food and nutrition policy consultancy EAS, said that EU efforts to harmonise regulations across its 27 member states has drawn interest across the globe, highlighting that in many areas including the food sector, Europe is fast becoming an exporter of regulation.
- Tate & Lyle Interim Results Announcement 2009
Tate & Lyle has announced their 2009 Interim results, reporting the Group's performance, before the impact of exchange translation, remains on track to meet our expectations for the full year.
- NPI Daily - Top of The News for Nov. 6, 2009 - National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters
Nature's Sunshine Products Reports FY09 Q3 Operating Results; SunOpta Announces FY09 Q3 Results; Tate & Lyle Interim Results Announcement 2009; NOW Foods Receives the 2009 Illinois Governor's Sustainability Award; Transport-C Supports Vitamin Angels at SSW; Cantox at Supplyside West; New Support Showing Immunoglobulin Supplementation Enhances Immune System; FDA Warning: Over-the-Counter Sex Enhancement Drug May Cause 'Dangerously' Low Blood Pressure; EPAX AS Achieves 'Friend of the Sea' Certification; National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters; Fast-C™ At SupplySide West: US Clinical Trials Data Available In Booth ; Nutty Flavor & Healthy Boost of Omega-3 Make Hemp Seed an Ideal Ingredient; DSM's tensVida® Recognized for Innovative Development; Nutrition 21 Announces Addition of Innovative New Probiotic + Omega-3 Fish Oil Combination Product; Glanbia Nutritionals Offers More Than Ingredients for Nutritional Beverages; Whole Foods Market(R) Offers Natural Solutions to Help Build Up Body Defenses With Immune System Support; Doug Reyes Joins Embria as Regional Sales Manager; Michael F. Hines Joins Board of General Nutrition Centers, Inc.; Dr. Arnold Hirsch Celebrates 50th Anniversary with the American Chemical Society
- NPI Daily - Top of The News for Nov. 6, 2009 - National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters
Nature's Sunshine Products Reports FY09 Q3 Operating Results; SunOpta Announces FY09 Q3 Results; Tate & Lyle Interim Results Announcement 2009; NOW Foods Receives the 2009 Illinois Governor's Sustainability Award; Transport-C Supports Vitamin Angels at SSW; Cantox at Supplyside West; New Support Showing Immunoglobulin Supplementation Enhances Immune System; FDA Warning: Over-the-Counter Sex Enhancement Drug May Cause 'Dangerously' Low Blood Pressure; EPAX AS Achieves 'Friend of the Sea' Certification; National Organic Standards Board Votes to Crack Down on Organic Personal Care Cheaters; Fast-C™ At SupplySide West: US Clinical Trials Data Available In Booth ; Nutty Flavor & Healthy Boost of Omega-3 Make Hemp Seed an Ideal Ingredient; DSM's tensVida® Recognized for Innovative Development; Nutrition 21 Announces Addition of Innovative New Probiotic + Omega-3 Fish Oil Combination Product; Glanbia Nutritionals Offers More Than Ingredients for Nutritional Beverages; Whole Foods Market(R) Offers Natural Solutions to Help Build Up Body Defenses With Immune System Support; Doug Reyes Joins Embria as Regional Sales Manager; Michael F. Hines Joins Board of General Nutrition Centers, Inc.; Dr. Arnold Hirsch Celebrates 50th Anniversary with the American Chemical Society
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Gencor Announces Study Results
Gencor has announced a new human clinical study was recently completed in Australia on Testofen, Gencor's proprietary extract of fenugreek, to evaluate its effect on libido in healthy men.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Carlson Laboratories Receives Better Nutrition Best of Supplements Awards for 2009
Carlson Laboratories has received awards for three of its products in this year's Best of Supplements Awards presented by Better Nutrition Magazine.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Sharp-GPC™ 45F by Enzymotec
Enzymotec has recently launched a liquid product called Sharp-GPC™ 45F to improve mental function and impede memory related cognitive decline.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Natural Products Foundation Representatives Meet with Federal Regulators on Truth in Advertising Campaign
The Natural Products Foundation recently met with officials from both U.S. Food and Drug Administration and Federal Trade Commission to turn over the names of 10 companies that have continued to make drug or disease claims in their advertising and other promotional materials.
- Taming Fear of the H1N1 Flu Vaccine
- Taming Fear of the H1N1 Flu Vaccine
- Natural Cold and Flu Remedies: Do They Help?
- Natural Cold and Flu Remedies: Do They Help?
- Exercise as Pain Therapy
- Exercise as Pain Therapy
|
Food supplement companies looking for strategic solutions for launching food supplements across Europe can find answers at a one-day intensive workshop organised by international food and nutrition policy consultancy EAS.
The workshop, which is being held for the third time this year due to its popularity, is titled ‘Building a Regulatory Strategy for Marketing Food Supplements in Europe: The key steps to a successful product launch’, and will take place on October 9 in Brussels.
Participants will be taken through a step-by-step process for launching food supplements in the European market – from product entrance strategies to advice on regulations for nutritional and herbal ingredients; information on novel foods procedures and labelling, and the next steps for health claims.
An up-to-date analysis of the most recent regulatory developments in the EU, such as the current climate for herbal ingredients; maximum levels for vitamins and minerals; implications and potential interpretations of the proposed EU Novel Foods Regulation, and health claims will also be presented.
“Navigating the maze of current regulations and making the right strategic judgements in the light of emerging regulatory changes is not easy for companies, particularly at this time”,” said Pieter Lagae, EAS Regulatory Adviser. “This workshop is targeted at guiding companies through the issues and challenges they will meet along the way.”
The workshop will be led by Mr Lagae; EAS Nutritional Product Regulatory Affairs Manager Stefanie Geiser; Katarina Wagner, Regulatory Manager of Nutritional Products; and Scientific and Regulatory Affairs Manager Efi Leontopoulou.
Participants will also benefit from a 45-minute session at the end of the day on the different rules and regulations for accessing the food supplement market in Asia. The session will be presented by Wai Mun Poon, Regional Regulatory Affairs Manager of EAS Asia, which is based in Singapore.
The EAS workshop is limited to 25 participants in order to maximise the value for attendees. For the full workshop programme or to register for the event, visit www.eas.eu or email cindygarcet@eas.eu
|